Adverse drug events (ADEs) are a significant cause of emergency department (ED) visits in North America and are frequently misdiagnosed. Despite evidence supporting improved health care outcomes for ED patients who have a pharmacist-led medication review, EDs do not have sufficient clinical pharmacists to perform medication reviews on all patients. The study reviewed in this article aimed to validate clinical decision rules for use by clinical pharmacists and physicians to prioritize ED patients with ADEs.
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Unfortunately, 20% to 50% of ADEs are not recognized by emergency and inpatient unit physicians. [7] [8] [9] [10] When ADEs are not recognized and corrected, inappropriate medication use continues, resulting in excess morbidity and health care resource utilization.
Clinical pharmacists are trained to focus on medication management and are more likely to recognize medication-related ED presentations than physicians. 11 However, clinical pharmacists are a scarce resource and not available in many centers.
In centers where they are available, routine medication review in all patients presenting to the ED is not feasible. Evidence-based criteria to enhance the identification and treatment of ADEs are needed to ensure that high-risk patients are evaluated by clinical pharmacists and to improve their outcomes.
ARTICLE SUMMARY
This is a prospective cohort study performed in two Canadian teaching hospitals. The study set out to validate two previously derived clinical decision rules (CDRs) used to identify incoming ED patients with ADEs. Validation of these two rules was done by identifying their diagnostic accuracy in a new cohort of ED patients. A secondary goal was to evaluate the accuracy of data collected by nurses, to determine whether the rules could be applied by nurses. From the derivation study, it was hypothesized that at least one of the rules would have a sensitivity of ≥90% in identifying moderate or severe ADEs.
Rule 1 Rule 2
QUALITY ASSESSMENT This is a prospective, multicenter study that focused on ED patients and included a broad spectrum of patients and clinicians. It was representative of a sample of patients who presented to the ED during daytime hours. This likely results in selection bias, however, in most settings that have clinical pharmacists, they work during daytime hours and thus the study is pragmatic for these centers. Clinical pharmacists were able to interpret individual predictor variables and score the CDR reliably and accurately. However, when applied by nurses, the decision rule items were recorded inaccurately. It is unclear whether the effect of the CDRs was large enough and precise enough to be clinically significant.
KEY RESULTS
A total of 1,529 patients were enrolled over a 1-year period at three hospitals. The mean age was 59 years and 56% were female. The median number of prescribed medications was five. A total of 184 patients (12%) were diagnosed with a total of 202 moderate or severe adverse drug reactions. There were no fatalities observed in the study attributed to ADEs.
Primary Outcome
The primary outcome was identifying patients with moderate or severe ADEs. Both rules had a sensitivity of greater than 90% for identifying ADEs. Variables strongly associated with ADEs included: age, use of opioids, antihypertensives and antibiotics, recent medication changes, and number of prescription medications.
• Rule 1 had a sensitivity of 91.3% (95% CI = 86.3%-95.0%) and a specificity of 37.9% (95% CI = 35.3%-40.6%).
• Rule 2 had a sensitivity of 95.7% (95% CI = 91.6%-98.1%) and a specificity of 22.8% (95% CI = 20.6%-25.2%).
Secondary Outcomes
• Clinical pharmacist's and treating physician's outcome assessment was concordant in 90% of the cases.
• Application of the CDRs by nursing staff was inconsistent and inaccurate.
• In cases that were ultimately attributed to ADEs, emergency physicians did not attribute the presentation to a drug 35% of the time.
• Emergency physicians were uncertain about whether an ADE had occurred in an additional 16%.
AUTHORS' COMMENTS
The author concluded that this "study validated clinical decision rules that can be applied by clinical pharmacists to limit the number of patients requiring medication review, while identifying the majority of patients presenting with clinically significant adverse drug events." In speaking with the primary author, we discovered that the implementation study for these CDRs was actually performed and published prior to this study. 12 This was due to the specifics of the grant funding provided for the project. The implementation study showed a small reduction in hospital length of stay for patients under 80 years of age who had an early pharmacist-led medication review; however, there was no effect on patients over 80 years of age. Dr. Hohl suggested that this may have been due to several limitations, including the quasi-randomized nature of that study as well as the inability to separate alternate level of care days from the entire length of stay. She suggests that the time elderly patients spend in hospital awaiting increased levels of care may have significantly altered the study results, and future studies should only include hospital length of stay for purely medical management.
TOP SOCIAL MEDIA COMMENTARY
This week's episode was highlighted on the Life in the Fast Lane Review #345 as the best free open-access emergency medical education (#FOAMed) of the week.
Comments From Twitter @Rick_Pescatore
PharmDs have a body of knowledge that I think is particularly useful to the emergency physician due to the wide array of pathology, need for adaptation in critical scenarios, and patient misadventures in street pharmacology.
Twitter Poll Blog Discussion From David Beach in Picton, Ontario
There is no technical reason these days that hospital ER EHRs could not provide us with drug interaction, warnings, etc. based on the drugs themselves, the patient's age and even lab values. It is all there in the database. In small towns, you are more likely to have previous lab data on file (the 'captive audience' of a rural hospital) so that even before the patient left triage, you could have a pretty good analysis of what's going on from a pharmacologic standpoint.
This 'augmentation' of our brains, 'decision support' type of software isn't a new idea nor is it something than can't be implemented. It just hasn't.
Is it cheaper than having a pharmacist at your elbow? Or better? Dunno [sic] . Software is expensive and is far from perfect. But it would be available 24/7.
Response from lead author, Dr. Corinne Hohl That's a great point. I don't think it's either or though.
The decision support itself will never supplant the pharmacist's or physician's diagnostic impression.
You can certainly have a pretty straightforward ADE due to a toxic drug level, but even then you have to decide whether to discontinue, adjust or replace the medication. That is not always straightforward. Interestingly, most clinically significant ADEs do not present with toxic drug levels (e.g., delirium) and require ruling out alternative diagnoses. The pharmacists will often ensure continuity of care, so follow the patient up on the ward if they decide to de challenge the patient. So, I think that having an automated decision support system, with a subsequent referral pathway allows you to ensure not only that medications are appropriately managed from them, but that the possibility of an ADE diagnosis is not forgotten The best part about it, in my experience, is the pharmacists' will often phone the GP.
Paper-in-a-pic from Kirsty Challen, @KirstyChallen
TAKE-TO-WORK POINTS
Use of a clinical decision rule by clinical pharmacists and ED physicians can help identify patients at risk for adverse drug events in the ED.
